Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Imiquimod, Garenoxacin Recommended for Approval
June 11, 2007
- Chuikyo Starts Discussing FY2008 Drug Pricing Reform
June 11, 2007
- Combined Sales, Profits of 4 Major Generic Firms Show Double-Digit Increases
June 11, 2007
- Taiyo Yakuhin: Sales Up but Ordinary Profits Down due to Aggressive Investment
June 11, 2007
- Towa: Operating Profits Up 84% as a Result of "Reasonable Pricing Policy"
June 11, 2007
- Suzuken Launches Given Imaging's Capsule Endoscope
June 11, 2007
- Sawai: Investment for Future Growth Cuts Profits Despite 28.9% Rise in Sales
June 11, 2007
- Given Imaging's Capsule Endoscope Spotlighted at JGES Meeting
June 11, 2007
- Trade-Off Concept Should Underlie New Pricing System: Dr Aoki
June 11, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 11, 2007
- Lack of Experienced CRAs Decelerates Growth of CRO Business: Mr Nakamura of CMIC
June 11, 2007
- Japan-Specific GCP Requirements Must Be Eliminated: SJP Seminar
June 11, 2007
- EPS to Aggressively Hire New Graduates
June 11, 2007
- R&D NEWS IN BRIEF
June 11, 2007
- Early Price Offering by Wholesalers Essential to Expedite Price Negotiation Process: Korosho
June 11, 2007
- REPORTER'S EYE／Incidence of NSAID-Induced Ulcers on the Rise in Japan
June 11, 2007
- Korosho Should Also Listen to Small Pharmacy Chains: Mr Kashiwagi
June 11, 2007
- Time to Launching of Anticancer Agents to Be Shortened by 2.5 Years: Korosho Council
June 11, 2007
- Further Efforts Needed to Improve Business Practices: Mr Matsutani
June 11, 2007
- SURVEY／Arrhythmia, Heart Disease Recognized as Risk Factors of Stroke by Only 40% of Japanese
June 11, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…